Sriram S, Topham D J, Carroll L
J Immunol. 1987 Sep 1;139(5):1485-9.
Treatment with monoclonal antibodies directed against the IA antigens of the MHC is known to alter the course and prevent a number of experimental autoimmune diseases. To determine whether the treatment in vivo with anti-IA antibodies is haplotype-specific, we studied the development of EAE in F1 (SJL/J X BALB/c) mice following anti-IA antibody therapy. We report that treatment of animals with monoclonal antibody directed against the high responder allele product, I-As, was successful in preventing disease when therapy was begun either at the time of immunization with antigen, or following passive transfer of MBP-sensitized T cells. Therapy with antibody directed to the low responder allele product (I-Ad), while effective when used at the time of immunization with antigen, was ineffective following passive transfer of MBP-sensitized lymphocytes.
已知用针对主要组织相容性复合体（MHC）IA抗原的单克隆抗体进行治疗可改变病程并预防多种实验性自身免疫性疾病。为了确定体内抗IA抗体治疗是否具有单倍型特异性，我们研究了抗IA抗体治疗后F1（SJL/J×BALB/c）小鼠实验性自身免疫性脑脊髓炎（EAE）的发展情况。我们报告称，当在抗原免疫时或髓鞘碱性蛋白（MBP）致敏T细胞被动转移后开始治疗时，用针对高反应性等位基因产物I-As的单克隆抗体治疗动物成功预防了疾病。用针对低反应性等位基因产物（I-Ad）的抗体治疗，虽然在抗原免疫时使用有效，但在MBP致敏淋巴细胞被动转移后无效。
